```html

Keratoconus (Advanced)

Overview

Keratoconus is a progressive, non‑inflammatory thinning and cone‑shaped protrusion of the cornea, the clear front surface of the eye. This distortion disrupts the eye’s ability to focus light, leading to blurred or distorted vision that cannot be fully corrected with standard glasses.

Who it affects: The condition typically begins in the teens or early twenties, a time when the cornea is still developing. While both sexes are affected, studies suggest a slightly higher prevalence in males (≈55%). It occurs worldwide, in every ethnic group, but is more common among people of Asian, Middle‑Eastern, and Mediterranean descent.

Prevalence: Epidemiological data varies because many cases are mild and go undiagnosed. Current estimates indicate that 1 in 2,000–3,000 people have keratoconus, with about 5–10 % progressing to an advanced stage that requires surgical intervention. In the United States, the CDC reports roughly 150,000 individuals living with clinically significant keratoconus.<sup>1</sup>

Symptoms

Symptoms often start subtly and become more pronounced as the disease advances. In the advanced stage, patients usually experience a combination of the following:

• Progressive visual blur: Vision worsens despite updating glasses.
• Distorted or “ghost” images: Straight lines appear wavy (asterism).
• Increased sensitivity to bright lights (photophobia): Discomfort in sunlight or glare.
• Frequent changes in eyeglass prescription: Refractive errors shift quickly.
• Frequent eye rubbing: Often a response to irritation but can worsen the condition.
• Halos around lights: Particularly at night, making driving hazardous.
• Reduced contrast sensitivity: Difficulty distinguishing subtle shades.
• Eye strain and fatigue: Especially during reading or computer work.
• Corneal scarring (in advanced disease): May cause a “white spot” in the visual axis.

When the cornea becomes extremely thin (≤350 µm), patients may also notice a sudden drop in vision or increased discomfort, signaling that urgent evaluation is needed.

Causes and Risk Factors

The exact cause of keratoconus is unknown, but researchers believe it results from a combination of genetic, environmental, and biomechanical factors.

Genetic predisposition

• First‑degree relatives have a 6–10 % risk of developing the disease.
• Associated genes include VSX1, COL5A1, and other loci related to collagen structure.

Environmental & behavioral factors

• Chronic eye rubbing: Mechanical trauma accelerates stromal thinning.
• Allergic eye disease: Conditions such as vernal keratoconjunctivitis increase rubbing.
• Contact lens wear: Improper fitting or extended wear can exacerbate corneal stress.

Systemic associations

• Down syndrome (up to 30 % prevalence of keratoconus).
• Marfan syndrome, Ehlers‑Danlos syndrome, and other connective‑tissue disorders.
• Atopic diseases (asthma, eczema) that promote frequent rubbing.

Demographic risk factors

• Age 10–35 years (peak onset).
• Male sex (slightly higher incidence).
• Ethnicity: Higher rates in South Asian, Middle Eastern, and Mediterranean populations.

Diagnosis

Early detection improves outcomes, but advanced keratoconus requires a thorough assessment to guide treatment.

Clinical examination

• Snellen visual acuity: Baseline measurement of distance vision.
• Slit‑lamp biomicroscopy: Identifies corneal thinning, Vogt’s striae (stress lines), Fleischer’s ring (iron deposits), and cone apex.
• Retinoscopy: Detects irregular astigmatism.

Imaging and topographic tests

• Corneal topography (Placido‑disc or Scheimpflug): Generates curvature maps that reveal the cone shape and severity (e.g., Amsler‑Krumeich classification).
• Pachymetry: Measures corneal thickness; values < 400 µm suggest advanced disease.
• Anterior segment Optical Coherence Tomography (AS‑OCT): Provides cross‑sectional images to assess stromal integrity and depth of ectasia.
• Corneal tomography: Combines curvature and thickness data to predict progression.

Additional tests (if needed)

• Wavefront aberrometry – quantifies higher‑order aberrations causing glare and halos.
• Dry‑eye evaluation – because ocular surface disease can worsen visual quality.

Treatment Options

Management aims to halt progression, improve visual acuity, and address corneal irregularities. In advanced keratoconus, the therapeutic spectrum expands from conservative measures to surgical interventions.

Non‑surgical therapies

• Corrective lenses:
  • RGP (rigid gas‑permeable) lenses – flatten corneal irregularities.
  • Hybrid lenses (RGP center with soft skirt) – improve comfort.
  • Scleral lenses – vault the cornea, providing excellent optics for severe cones.
• Contact lens training: Proper fitting and hygiene reduce complications.
• Topical anti‑inflammatory drops: For associated allergic eye disease to limit rubbing.

Corneal collagen cross‑linking (CXL)

Considered the gold‑standard for halting progression:

• Standard (epi‑off) CXL: Riboflavin drops activated by ultraviolet‑A (UVA) light; creates new covalent bonds in stromal collagen.
• Accelerated & epi‑on protocols: Shorter treatment times; useful when corneal thickness is borderline.
• Success rates: ≥70 % of eyes show ≥1 D flattening and stabilization over 5 years.<sup>2</sup>

Surgical options for advanced disease

• Intacs® intracorneal ring segments: Plastic inserts placed in the mid‑stroma to flatten the cone and reduce irregular astigmatism.
• Phakic intra‑ocular lenses (pIOL): Correct high myopia when corneal optics are insufficient.
• Topography‑guided photorefractive keratectomy (PRK) combined with CXL: Reshapes the cornea and then stabilizes it.
• Penetrating keratoplasty (PK) or deep anterior lamellar keratoplasty (DALK): Full‑ or partial‑ thickness corneal transplant for eyes with severe scarring or thinning < 350 µm.

Lifestyle & supportive measures

• Avoid chronic eye rubbing – use cold compresses or antihistamine drops for itch relief.
• Protect eyes from UV exposure – wear sunglasses with 100 % UVA/UVB protection.
• Regular follow‑up (every 6–12 months) to monitor progression.

Living with Keratoconus (advanced)

Advanced keratoconus can impact daily activities, but appropriate management helps maintain independence and quality of life.

Visual aids and adaptive tools

• High‑quality sclerals or hybrid lenses for most tasks.
• Low‑vision magnifiers for reading and fine work.
• Electronic devices with adjustable font size and high‑contrast modes.

Work and school accommodations

• Request anti‑glare screen protectors and proper lighting.
• Allow extra time for eye‑related breaks during prolonged screen use.
• Consider “quiet room” for exams if visual discomfort is an issue.

Eye‑health maintenance

• Maintain a strict lens‑care routine – replace lenses as advised.
• Use preservative‑free artificial tears to keep the ocular surface moist.
• Schedule annual comprehensive eye exams, or sooner if vision changes.

Psychosocial support

• Join support groups (e.g., Keratoconus International, local ophthalmology clinics).
• Consider counseling if anxiety or depression develops due to vision changes.

Prevention

Because genetic predisposition cannot be altered, prevention focuses on modifiable behaviors:

• Stop or limit eye rubbing: Treat underlying allergies promptly.
• Use protective eyewear: UV‑blocking sunglasses reduce UV‑induced collagen damage.
• Avoid smoking: Tobacco smoke may impair corneal healing.
• Regular screening for at‑risk individuals: Family members of patients should undergo baseline topography by age 10–12.

Complications

If advanced keratoconus is left untreated, several serious complications can arise:

• Corneal scarring: Permanent visual loss that may necessitate transplant.
• Corneal hydrops: Sudden influx of fluid into the stroma causing marked swelling, pain, and rapid vision loss.
• Contact lens intolerance: Leads to chronic hypoxia or infection.
• Increased risk of infectious keratitis: Particularly with poorly fitting lenses.
• Post‑surgical graft rejection (for PK/DALK): Requires lifelong monitoring.

When to Seek Emergency Care

---

Sources:

1. Mayo Clinic. “Keratoconus.” Updated 2023. https://www.mayoclinic.org
2. American Academy of Ophthalmology. “Corneal Collagen Cross‑Linking (CXL).” 2022. https://www.aao.org
3. World Health Organization. “Global Eye Health Data.” 2021.
4. Cleveland Clinic. “Keratoconus Treatment Options.” 2024.
5. National Eye Institute (NEI). “Keratoconus Fact Sheet.” 2022.

```